fda seeks more study of novartis medication zurich novartis ag said the food and drug administration has requested another study on the experimental diabetes drug galvus before approving it delaying the launch of one of the companys most important new products by at least a year the drug maker based in basel switzerland said the regulator issued a so called approvable letter for galvus meaning the fda is prepared to approve the investigational medicine only if certain conditions are met the fda requested a clinical study to demonstrate the safety and effectiveness of the drug in patients with kidney impairments galvus was one of two medications novartis hoped to launch this year the other is tekturna a high blood pressure treatment "we will meet with the fda and clarify exactly what data they need " said james shannon head of development at novartis 
